Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $6.20 million. The enterprise value is -$684,626.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 1.54 million shares outstanding. The number of shares has increased by 1.34% in one year.
| Current Share Class | 1.54M |
| Shares Outstanding | 1.54M |
| Shares Change (YoY) | +1.34% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 7.28% |
| Owned by Institutions (%) | 3.80% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.44 |
| Forward PS | 8.38 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.96
| Current Ratio | 6.96 |
| Quick Ratio | 6.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.48% and return on invested capital (ROIC) is -30.40%.
| Return on Equity (ROE) | -45.48% |
| Return on Assets (ROA) | -27.25% |
| Return on Capital (ROIC) | -30.40% |
| Revenue Per Employee | $630,857 |
| Profits Per Employee | -$1.02M |
| Employee Count | 4 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.50% in the last 52 weeks. The beta is 2.26, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.26 |
| 52-Week Price Change | +28.50% |
| 50-Day Moving Average | 3.91 |
| 200-Day Moving Average | 3.97 |
| Relative Strength Index (RSI) | 48.75 |
| Average Volume (20 Days) | 33,036 |
Short Selling Information
The latest short interest is 14,832, so 0.96% of the outstanding shares have been sold short.
| Short Interest | 14,832 |
| Short Previous Month | 16,776 |
| Short % of Shares Out | 0.96% |
| Short % of Float | 1.26% |
| Short Ratio (days to cover) | 0.77 |
Income Statement
In the last 12 months, XBIO had revenue of $2.52 million and -$4.08 million in losses. Loss per share was -$2.66.
| Revenue | 2.52M |
| Gross Profit | 2.52M |
| Operating Income | -4.36M |
| Pretax Income | -4.47M |
| Net Income | -4.08M |
| EBITDA | n/a |
| EBIT | -4.36M |
| Loss Per Share | -$2.66 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 6.84M |
| Total Debt | n/a |
| Net Cash | 6.84M |
| Net Cash Per Share | $4.44 |
| Equity (Book Value) | 7.04M |
| Book Value Per Share | 4.56 |
| Working Capital | 6.02M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.94M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.94M |
| FCF Per Share | -$1.90 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -172.82% and -161.58%.
| Gross Margin | 100.00% |
| Operating Margin | -172.82% |
| Pretax Margin | -161.58% |
| Profit Margin | -161.58% |
| EBITDA Margin | n/a |
| EBIT Margin | -172.82% |
| FCF Margin | -170.60% |